Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28782346 | 0.98 | CA2 (0.56) | CA2KDM4EALDH1A1CES2CES1 | |
| SCHEMBL11290860 | 0.82 | CA2 (0.80) | CA2KDM4EALDH1A1CES2CES1 | |
| SCHEMBL238714 | 0.78 | AKR1B1 (0.61) | CA2KDM4EALDH1A1CES2CES1 | |
| Water SCHEMBL27968188 | 0.78 | CES1 (0.61) | CA2ALDH1A1CES2CES1AKR1B1 | |
| SCHEMBL10822384 | 0.77 | CAPN1 (0.50) | CA2KDM4EALDH1A1LMNATDP1 | |
| SCHEMBL21381425 | 0.76 | CES1 (0.36) | CA2ALDH1A1CES2CES1AKR1B1 | |
| Water SCHEMBL28074006 | 0.76 | CA2 (0.95) | CA2 | |
| SCHEMBL1948319 | 0.76 | HTR3E (0.44) | CA2 | |
| SCHEMBL4933643 | 0.76 | POLB (0.47) | CA2ALDH1A1CES2CES1AKR1B1 | |
| SCHEMBL28862196 | 0.76 | HDAC1 (0.45) | ALDH1A1LMNAADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD. (IL) | 2023-03-16 | — | — | US | claimed |
| WO-2021095032-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | METABOMED LTD (IL) | 2021-05-20 | — | — | WO | claimed |
| EP-3630115-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS | University Of Virginia Patent Foundation (US) | 2020-04-08 | — | — | EP | claimed |
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | claimed |
| WO-2018217757-A1 | COMPOSITIONS AND METHODS FOR PREPARING AND USING MITOCHONDRIAL UNCOUPLERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-11-29 | — | — | WO | claimed |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-06 | — | — | US | claimed |
| CN-108383828-A | 1 new, 2- as chemokine receptor modulators is bis--sulfamide derivative | 阿勒根公司 | 2018-08-10 | — | — | CN | claimed |
| CN-106049176-B | The surface sizing technique of high-strength corrugating medium | 东莞顺裕纸业有限公司 | 2018-04-03 | — | — | CN | claimed |
| US-9682955-B2 | Quinazoline derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| US-9682940-B2 | Indazole derivatives useful as CB-1 inverse agonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | claimed |
| EP-0362908-A2 | 1,4-Dihydropyridine dicarboxylic acid derivatives | ZAMBON GROUP S.p.A. (IT) | 1990-04-11 | — | — | EP | claimed |
| EP-0193227-B1 | PROCESS FOR THE PREPARATION OF ARYLGLYCIDYL ETHERS AND 3-SUBSTITUTED 1-ALKYLAMINO-2-PROPANOLS | GIST-BROCADES N.V. (NL) | 1990-04-11 | — | — | EP | claimed |
| EP-0352863-A2 | 1,4-Dihydropyridine dicarboxylic acid derivatives | ZAMBON GROUP S.p.A. (IT) | 1990-01-31 | — | — | EP | claimed |
| EP-0333938-A1 | 2-Hydroxy-3-aryloxy-propylamine derivatives having cardiovascular activity | ZAMBON GROUP S.p.A. (IT) | 1989-09-27 | — | — | EP | claimed |
| EP-0334164-A2 | Antihypertensive combination preparation | F. HOFFMANN-LA ROCHE AG (CH) | 1989-09-27 | — | — | EP | claimed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | claimed |
| EP-0057572-B1 | ALKANOLAMINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-07-31 | — | — | EP | claimed |
| US-4363808-A | N-(3-Phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1982-12-14 | — | — | US | claimed |
| US-4287194-A | Compositions with potentiated hypotensive effects | RICHTER GEDEON VEGYESZETI GYAR RT. (HU) | 1981-09-01 | — | — | US | claimed |
| EP-0034116-A2 | N-(3-phenoxy-2-hydroxypropyl)benzimidazole-1-alkanamines | BERLEX LABORATORIES, INC. (US) | 1981-08-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031618-A1 | BENZIMIDAZOLE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS | CNR1, GPR119, CNR2 | CA2 1286/4885KDM4E 3213/4885ALDH1A1 528/4885 |
| US-10118900-B2 | Benzimidazole derivatives useful as CB-1 inverse agonists | CNR1, GPR119, CNR2 | CA2 1288/4885KDM4E 3224/4885ALDH1A1 517/4885 |
| US-20230084927-A1 | GLUCOSE UPTAKE INHIBITORS AND USES THEREOF | SLC2A4, SLC2A1, SLC2A2 | CA2 554/4885KDM4E 2887/4885ALDH1A1 1014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.